Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18118180 | 0.98 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL847809 | 0.98 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL18118174 | 0.95 | HPGD (0.52) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL20251137 | 0.91 | MAPT (0.51) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL10404832 | 0.86 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL17660586 | 0.85 | ALDH1A1 (0.60) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL15247182 | 0.85 | CHKA (0.58) | ALDH1A1MAPTKDM4EGAAKMT2A | |
| SCHEMBL15247189 | 0.83 | ADRB1 (0.55) | ALDH1A1KDM4ELMNA | |
| SCHEMBL13904141 | 0.83 | MAPT (0.59) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL101926 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010641-A | Beta-substituted pyrrole derivative, preparation method and application thereof | 青岛农业大学 | 2022-09-06 | — | — | CN | claimed |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| EP-3838898-B1 | ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-06-07 | — | — | EP | disclosed |
| US-7732473-B2 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | NEUROTUNE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2009-06-25 | — | — | US | disclosed |
| US-20090105312-A1 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | ALDH1A1 983/4885MAPT 4661/4885KDM4E 2287/4885 |
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKB2, NFKBIA | ALDH1A1 4179/4885MAPT 1222/4885KDM4E 2482/4885 |
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | ALDH1A1 2995/4885MAPT 3785/4885KDM4E 4753/4885 |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | ALDH1A1 140/4885MAPT 2639/4885KDM4E 601/4885 |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | ALDH1A1 3412/4885MAPT 3441/4885KDM4E 2656/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | ALDH1A1 4642/4885MAPT 598/4885KDM4E 2603/4885 |
| US-20090105312-A1 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY | NUDT1, PDE7A, SLC7A1 | ALDH1A1 2054/4885MAPT 235/4885KDM4E 3013/4885 |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | OPRL1, GRIN3B, GRIN3A | ALDH1A1 1813/4885MAPT 1530/4885KDM4E 3994/4885 |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | ALDH1A1 2017/4885MAPT 3731/4885KDM4E 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.